- Home
- MNMD vs PFIS Comparison
MNMD vs PFIS Comparison
Compare MNMD & PFIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- PFIS
- Stock Information
- Founded
- MNMD 2019
- PFIS 1905
- Country
- MNMD United States
- PFIS United States
- Employees
- MNMD N/A
- PFIS N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- PFIS Major Banks
- Sector
- MNMD Health Care
- PFIS Finance
- Exchange
- MNMD Nasdaq
- PFIS Nasdaq
- Market Cap
- MNMD 541.7M
- PFIS N/A
- IPO Year
- MNMD N/A
- PFIS N/A
- Fundamental
- Price
- MNMD $6.68
- PFIS $51.32
- Analyst Decision
- MNMD Strong Buy
- PFIS
- Analyst Count
- MNMD 8
- PFIS 0
- Target Price
- MNMD $26.29
- PFIS N/A
- AVG Volume (30 Days)
- MNMD 1.2M
- PFIS 22.4K
- Earning Date
- MNMD 08-12-2025
- PFIS 07-24-2025
- Dividend Yield
- MNMD N/A
- PFIS 5.00%
- EPS Growth
- MNMD N/A
- PFIS N/A
- EPS
- MNMD N/A
- PFIS 2.14
- Revenue
- MNMD N/A
- PFIS $138,502,000.00
- Revenue This Year
- MNMD N/A
- PFIS $66.02
- Revenue Next Year
- MNMD N/A
- PFIS $4.37
- P/E Ratio
- MNMD N/A
- PFIS $23.03
- Revenue Growth
- MNMD N/A
- PFIS 43.82
- 52 Week Low
- MNMD $4.70
- PFIS $38.90
- 52 Week High
- MNMD $10.44
- PFIS $59.70
- Technical
- Relative Strength Index (RSI)
- MNMD 44.84
- PFIS 55.67
- Support Level
- MNMD $6.35
- PFIS $47.92
- Resistance Level
- MNMD $7.29
- PFIS $50.75
- Average True Range (ATR)
- MNMD 0.46
- PFIS 1.19
- MACD
- MNMD -0.10
- PFIS 0.11
- Stochastic Oscillator
- MNMD 19.65
- PFIS 69.67
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).